Patents Examined by Nizal S. Chandrakumar
  • Patent number: 11827622
    Abstract: The present invention relates to crystalline polymorphs of imidacloprid for effective pest management strategies at lower dosages. The present invention further relates to processes of preparing the crystalline polymorphs, and to methods of controlling pests using the novel crystalline polymorphs.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: November 28, 2023
    Inventors: Xiaolong Zhu, Jingxiang Yang, Chunhua T. Hu, Michael D. Ward, Bart Kahr
  • Patent number: 11820774
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: November 21, 2023
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • Patent number: 11819481
    Abstract: The present invention provides compositions and methods for treating hypertension and obstructive sleep apnea utilizing hydrogel compositions comprising drug amphiphiles with TRPM 7 antagonists for use in a subject, including use on the carotid body of a subject.
    Type: Grant
    Filed: January 24, 2022
    Date of Patent: November 21, 2023
    Inventors: Vsevolod Polotsky, Honggang Cui, Roxana Elena Mitrut, Mi-kyung Shin
  • Patent number: 11819503
    Abstract: The invention relates to the therapeutic use of olorofim, 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide in the prevention and treatment of a fungal infection caused by a Coccidioides species.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: November 21, 2023
    Assignees: F2G Ltd
    Inventors: Derek Law, John H. Rex, Michael Birch, Nathan P. Wiederhold, Thomas F. Patterson
  • Patent number: 11801256
    Abstract: A method of enhancing positive effects of a psychedelic, by pretreating an individual with an antidepressant, administering a psychedelic to the individual, and inducing a more positive psychological state in the individual with the antidepressant-psychedelic combination compared with the psychedelic alone. A method of enhancing positive effects of a psychedelic, by inhibiting serotonin transport in an individual, increasing levels of endogenous monoamines in the individual, and stimulating 5-HT2A receptors in the individual. A composition including an antidepressant and a psychedelic in the same dosage form.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: October 31, 2023
    Assignee: Universitätsspital Basel
    Inventors: Matthias Emanuel Liechti, Anna Margarete Becker
  • Patent number: 11793779
    Abstract: 2-Hydroxy-isocaproic acid (HICA), or an ester or amide derivative, an enantiomer or a pharmaceutically acceptable salt thereof, for use in prevention and/or treatment of a disease or condition involving degradation of cartilage and/or disruption of cartilage homeostasis and/or integrity is disclosed.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: October 24, 2023
    Assignee: Salarusta Oy
    Inventors: Timo Sorsa, Taina Tervahartiala, Tuomo Karila, Beniamin Cohen
  • Patent number: 11793817
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R1-R6 are as defined herein.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: October 24, 2023
    Assignee: Heptares Therapeutics Limited
    Inventors: Miles Stuart Congreve, Giles Albert Brown, Julie Elaine Cansfield, Benjamin Gerald Tehan
  • Patent number: 11787946
    Abstract: The present invention is generally directed to the synthesis and use of fluorophores. It is more specifically directed to the synthesis and use of deuterated fluorophores. In one case, the present invention provides a compound of the structure shown in FIG. 44.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: October 17, 2023
    Assignee: Howard Hughes Medical Institute
    Inventors: Luke Lavis, Jonathan B. Grimm
  • Patent number: 11779563
    Abstract: Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders using the oral cannabinoid pharmaceutical compositions are described.
    Type: Grant
    Filed: April 10, 2023
    Date of Patent: October 10, 2023
    Assignee: Curio IP, LLC
    Inventors: Edward M. Rudnic, Michael Bronfein
  • Patent number: 11779584
    Abstract: The disclosure relates generally to alpha polyglutamated pemetrexed, formulations containing liposomes filled with alpha polyglutamated pemetrexed, methods of making the alpha polyglutamated pemetrexed and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated pemetrexed and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: October 10, 2023
    Inventors: Clet Niyikiza, Victor Mandla Moyo
  • Patent number: 11779016
    Abstract: The present invention relates to a solution for resisting destruction of living plants and a related method. A solution including a buffered amine oxide admixed with at least one material selected from the group consisting of insecticides and fungicides is applied to the living plant and provides a synergistically effective greater resistance to living plant deterioration than any of the individual buffered amine oxide, insecticides and fungicides achieve. A related method is disclosed.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: October 10, 2023
    Assignee: KOP-COAT, INC.
    Inventors: Ronald W. Clawson, Jr., Hans A. Ward, Kenneth A. Cutler, Cameron R. Scott
  • Patent number: 11780815
    Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: October 10, 2023
    Assignees: City of Hope, California Institute of Technology
    Inventors: Binghui Shen, Judith Campbell, Li Zheng, Hongzhi Li, David Horne, Jun Xie, Kenneth Karanja
  • Patent number: 11780828
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein R1-R6 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as contraceptive agents.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: October 10, 2023
    Inventors: Ingrid Gunda Georg, Narsihmulu Cheryala
  • Patent number: 11771703
    Abstract: The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of a TGF?2-associated disease, disorder and/or condition, including, e.g., Scleroderma, other fibrotic disease, grade 4 glioblastoma (GBM) and/or Primary Open-Angle Glaucoma (POAG). The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of TGF?2-associated diseases, disorders and/or conditions.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: October 3, 2023
    Assignee: The Johns Hopkins University
    Inventors: Harry C. Dietz, Joseph Shin
  • Patent number: 11760726
    Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: September 19, 2023
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
  • Patent number: 11752127
    Abstract: The present technology relates to a method for treating anxiety or an anxiety-related disorder in an animal subject, the method comprising administering an effective amount of cannabidiol (CBD) to the animal subject.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: September 12, 2023
    Inventors: Justyna Kulpa, Dana M. Vaughn
  • Patent number: 11744896
    Abstract: Provided are CDK2-PROTAC compounds and pharmaceutical compositions thereof that can be used for specific degradation of the cyclin-dependent kinase 2 (CDK2) protein, for treatment of cancers and other CDK2 related diseases as well as for prevention and treatment of hearing loss.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: September 5, 2023
    Inventors: Jian Zuo, Santanu Hati, Marisa Laura Zallocchi, Robert Hazlitt, Jaeki Min
  • Patent number: 11738054
    Abstract: In one aspect, a method of preconditioning stem cells comprising exposing stem cells to low dose radiation (LDR) is provided. In another aspect, a population of preconditioned stem cells is provided, wherein the population of 5 preconditioned stem cells is obtained by exposing stem cells to LDR. Uses of the preconditioned stem cells are also provided. In other aspects, the stem cells are muscle stem cells.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: August 29, 2023
    Inventors: Dmitry Klokov, Soji Sebastian, Yevgeniya Le
  • Patent number: 11739103
    Abstract: The present disclosure provides processes for preparing a crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile and related intermediate compounds.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: August 29, 2023
    Assignee: Theravance Biopharma R&D LP, LLC
    Inventors: Norbert Kraut, Matteo Conza, Anja Huste, Vit Lellek, Bjorn Gielen, Christian Pater, Dimitar Filipov, Xiaojun Huang, Stephen Roseblade
  • Patent number: 11738089
    Abstract: Disclosed herein, are compositions comprising one or more molecular guidance system (MGS) peptides and a cytotoxic agent. Also described herein, are methods of administering the compositions to patients with cancer.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: August 29, 2023
    Assignee: SRI International
    Inventors: Kathlynn C. Brown, Curtis Allred, Michael McGuire